Home » Markets » Pfizer/BioNTech COVID-19 booster 95.6% effective against disease: study
Pfizer/BioNTech COVID-19 booster 95.6% effective against disease: study
Fox Business Flash top headlines for October 21
Check out what’s clicking on FoxBusiness.com.
Pfizer, Inc. and BioNTech SE announced Thursday that topline results from a Phase 3 trial found that a 30-microgram booster dose of the companies' vaccine showed a relative vaccine efficacy of 95.6% in individuals who had previously received the Pfizer/BioNTech primary two-dose series, when compared to those who did not receive a booster.
The trial included more than 10,000 people who were 16 years old or older and Pfizer said in a news release that the booster dose administered to the participants restored vaccine protection against COVID-19 "to the high levels achieved after the second dose."
MODERNA AND J&J COVID-19 BOOSTERS, MIXING AND MATCHING, AUTHORIZED BY THE FDA
The individuals were randomized to receive either a 30-microgram booster dose – the same dosage as in the primary series – or a placebo.
The midpoint between the second Pfizer/BioNTech vaccine dose and administration of either the booster dose or a placebo was around 11 months.
Symptomatic COVID-19 occurrence was measured from at least seven days after booster or placebo, with a median follow-up time of approximately two-and-a-half months.